An observational study in Pulmonary Thromboembolisms, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Pulmonary Embolism with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Pulmonary Embolism · Italy.
Among the 57 studies in Pulmonary Embolism with a site in Italy, this one is the 17th largest by planned enrollment of the 28 observational ones that give a count, is the only one that started in 2024, is one of 28 observational ones, and was the 55th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →6 of the 57 studies in Pulmonary Embolism with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy, Poland, Spain
Ages 18+
Azienda ULSS 8 Berica · Sites in Italy
Ages 18+
Inari Medical · Sites in Italy, France, Germany and 2 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
Penumbra Inc. · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 2
First in 1998; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 656 across the 28 interventional studies, 623 across the 28 observational. Of the 44 that completed or were terminated, 11 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 57 have an industry lead sponsor. The 10 most frequent:
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.
IRCCS Azienda Ospedaliero-Universitaria di Bologna has 5 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
3 of the studies in Pulmonary Embolism with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06143969Niguarda HospitalUltrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism | 2026-11-30 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
| NCT06761144IRCCS Azienda Ospedaliero-Universitaria di BolognaPulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Pulmonary Embolism with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary thromboembolism is a frequent complication of cancer; in some cases, it is diagnosed occasionally during diagnostic examinations as part of the regular follow-up of the disease. Not all patients diagnosed with thromboembolism present symptoms; therefore, after appropriate investigations during observation in the emergency room and/or a short hospitalisation in Emergency Medicine, they could be discharged home, avoiding lengthy hospitalisations that would have a considerable impact on their health and psychological condition.
The goal of this observational study is to compare the efficacy of several assessment scales for use by physicians to identify patients at low risk of developing serious complications of pulmonary embolism within 30 days of diagnosis, in order to be able to identify a group of low-risk patients who could be discharged early from the emergency department/emergency medicine safely.
What does participation in this study entail compared to the normal care you receive and what are your responsibilities as a participant? At the time of patient enrolment in the emergency room/emergency medicine, the data necessary for the calculation of 6 scoring systems will be collected, which will take approximately 5 minutes.
The patient enrolled in the study will be contacted by telephone in order to assess the state of health; the call will take approximately 1 minute and will take place 30 days after access to the emergency room.
Participation in the study does not entail any obligation or restriction, nor will it be charged for.
Cancer patients are at increased risk of developing thromboembolic complications, including pulmonary thromboembolism (PTE), with an annual incidence of 1:200. Not all patients with PTE present with symptoms suggestive of the disease, and nowadays, thanks in part to the technological development of radiological techniques that make it possible to visualise as far as the subsegmental branches of the pulmonary vasculature, the diagnosis of pulmonary embolism is steadily increasing. Therefore, we are increasingly seeing the diagnosis of Incidental Pulmonary Embolism (IPE), defined as 'an unsuspected pulmonary artery filling defect identified during CT scans performed for other reasons, usually during screening and follow-up of cancer pathology'. Patients with IPE are often asymptomatic, although in some cases, further investigation of the history and complaints reported by the patient may reveal some symptoms compatible with PTE.
The incidence of IPE in cancer patients ranges from 1.6 to 7.3%. In this study, patients who presented to the Emergency Department during the period from 01.01.2015 to 31.12.2019 will be consecutively enrolled in a retrospective manner and prospectively patients presenting to the Emergency Department for a period of two years from the approval of the study by the Ethics Committee and subsequent clearance by the Director General with a diagnosis of PTE in the course of active onco-haematological disease (pathology followed in an oncological/haematological and/or metastatic setting).
A 30 day follow-up will be carried out in order to record any major adverse events, like death, respiratory failure, or re-hospitalisation.
The study is observational, non-interventional. Patients will be treated according to clinical practice in accordance with the judgement of the physician.
The primary objective is to evaluate existing and used prognostic scores (HESTIA, PESI, sPESI, POMPE-C, EPIPHANY Index, RIETE) in oncological patients with incidental pulmonary embolism in order to identify the one with the greatest effectiveness in identifying patients at low risk of major adverse events at 30 days, and therefore safely discharged early from the emergency department.
The secondary objective is to identify, in the group of cancer patients with pulmonary embolism (incidental and symptomatic), which score among those used has the best performance in identifying patients at low risk of major adverse events at 30 days, in order to identify a group of patients who can be discharged early and safely.
The outcome to be assessed is 30-day mortality in patients identified as low risk with the scores used. In addition, evaluate a composite endpoint at 30 days: hospitalisation for PTE diagnosis-related problems/respiratory failure-related illness/mortality at 30 days.
It should be noted that the diagnosis of acute respiratory failure will be made according to the diagnostic criteria known in the literature. This diagnosis imposes the need for oxygen therapy, so the patient with respiratory failure will not be discharged home, necessarily requiring hospitalisation, which is an adverse event for the proposed study.
Outcomes will be assessed using computerised records and PS reports. Patients over 18 years of age attending the General Hospital / Emergency Medicine IRCCS AOU of Bologna Policlinico di S.Orsola with a diagnosis of PTE and onco-haematological pathology will be included. The duration of the study is estimated to be 3 years: 6 months for retrospective data collection, 24 months for prospective enrolment and 6 months for data processing.
It should be noted that patients will be enrolled at the first admission to the Emergency Department, therefore they will be in charge of the Emergency Department and not in an in-patient setting. The enrolled patients could be retained in the OBI regime (always afferent to the Emergency Department) to complete the basic diagnostic-therapeutic procedure before eventual admission to a medical, intensive-sub-intensive ward or discharge to home. Any admission to Emergency Medicine, following discharge from the Emergency Department, will be considered as admission to an internist environment.
Patient characteristics will be reported as mean +/- standard deviation for continuous variables and as numerosity and frequency for categorical variables. Sensitivity, specificity, positive and negative predictive values will be calculated for each score. Monovariate statistics using Kaplan Meier curves will be used to assess the association of each score with 30-day mortality. In addition, ROC (Receiver-operating Characteristic) curve analysis will be used to evaluate the performance of each score. Statistical significance will be defined for values of p\<0.05 and analyses will be conducted using SPSS version 28 software (IBM Corp., Armonk, NY, USA).
Patients with active oncohematological pathology, over 18 years of age, with a diagnosis of pulmonary embolism attending the Emergency Department of the IRCSS Azienda Ospedaliero-Universitaria di Bologna
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluate mortality in patients at low risk of major adverse events (death/respiratory failure/hospitalisation)
The primary objective is to evaluate the already existing and used prognostic scores (HESTIA, PESI, sPESI, POMPE-C, EPIPHANY Index, RIETE) in cancer patients with incidental pulmonary embolism in order to identify the one with the greatest effectiveness for identifying patients at low risk of major adverse events at 30 days, who can therefore be discharged early and safely from the emergency department.
Time frame: From enrollment to the follow-up at 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.
Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 35 months is below that.
Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →